Restructuring And New Pharmaceuticals Will Improve Operational Efficiency By 2026

AN
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
Published
24 Nov 24
Updated
31 Jul 25
AnalystConsensusTarget's Fair Value
€28.37
3.1% undervalued intrinsic discount
31 Jul
€27.50
Loading
1Y
2.0%
7D
-5.0%

Author's Valuation

€28.4

3.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 3.20%

Shared on23 Apr 25
Fair value Increased 3.54%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 7.39%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 4.10%

AnalystConsensusTarget has increased discount rate from 5.2% to 5.8%.

Shared on02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 1.78%

AnalystConsensusTarget has decreased revenue growth from 1.2% to 1.0%.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Decreased 2.26%

AnalystConsensusTarget has increased profit margin from 5.7% to 6.4% and decreased future PE multiple from 11.5x to 10.3x.